Trevi Therapeutics (TRVI) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
UroGen Pharma (URGN) has outperformed Trevi Therapeutics (TRVI) over the past year, gaining 113.4% versus a gain of 30.6%. Over five years, TRVI leads with a +894.2% price change compared with +117.3% for URGN. Trevi Therapeutics is the larger company by market cap ($1.86 billion vs $1.81 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TRVI | URGN |
|---|---|---|
| Share price | $13.08 | $37.06 |
| Market cap | $1.86B | $1.81B |
| 1-day change | +1.99% | +0.22% |
| YTD return | +2.44% | +57.90% |
| 1-year return | +30.60% | +113.39% |
| 5-year return | +894.19% | +117.27% |
| Forward P/E | — | 13.26 |
| EPS (TTM) | $-0.35 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $109.79M |
| Revenue growth (YoY) | — | +21.45% |
| Net income (latest FY) | $-42.76M | $-153.49M |
| Gross margin | — | 88.66% |
| Operating margin | — | -113.73% |
| Net margin | — | -139.81% |
| 52-week high | $20.22 | $50.81 |
| 52-week low | $9.28 | $15.86 |
| Distance from 52-week high | -35.31% | -27.06% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +115.44% | +61.90% |
| Average volume | 2.03M | 849.01K |
| Shares outstanding | 142.48M | 48.88M |
| Employees | 34 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed TRVI by 82.8 percentage points over the past year.
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
TRVI vs URGN FAQ
Which is bigger, Trevi Therapeutics or UroGen Pharma?
Trevi Therapeutics (TRVI) is larger, with a market capitalization of $1.86B compared with $1.81B for UroGen Pharma (URGN).
Which stock has performed better over the past year, TRVI or URGN?
URGN returned +113.39% over the past 12 months, compared with +30.60% for TRVI (price return, excluding dividends). Past performance does not predict future results.
Are Trevi Therapeutics and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.